Drugs That May Affect or Alter Radiopharmaceutical Distribution in Skeletal Imaging 99mTcMDP or 99mTcHDP
|
| Aluminum carbonate | Unexpected organ uptake: liver and kidney) |
| Aluminum hydroxide | Unexpected organ uptake (liver, kidney and increased vascular uptake) |
| Amphotericin 8 | Unexpected organ uptake (liver and genitourinary) |
| Calcitonin | Extraosseous soft tissue uptake |
| Calcium heparinate | Extraosseous soft tissue and muscle uptake |
| Cimetidine | Breast uptake |
| Cyclophosphamide | Intense renal parenchymal/genitourinary uptake |
| Dialysate | Gastric uptake |
| Doxorubicin | Intense renal parenchyma and diffuse myocardium uptake |
| Estrogen | Breast uptake |
| Ferrous gluconate | Decreased skeletal uptake; increased renal and liver uptake |
| Ferrous sulfate | Decreased skeletal uptake; increased renal and liver uptake |
| Gentamicin | Intense renal parenchymal uptake |
| Heparin (SC) | Extraosseous soft tissue uptake |
| Iodinated contrast media | Decreased bone uptake; increased liver uptake |
| Iron dextran (IM) | Decreased bone uptake and soft tissue uptake |
| Iron therapy (long term) | |
| Meperidine (IM) | Increased bone, muscle, and soft tissue uptake |
| Phospo-soda | Decreased bone uptake |
| Potassium phosphate | Intense renal, genitourinary and liver uptake |
| Sodium diatrizoate | Decreased bone uptake; increased renal uptake |
| Steroid therapy (long term) Vincristine | Intense renal parenchymal and genitourinary uptake |
Return to Abnormal Distribution Menu
Return to the Table of Content